case_images: PMC8710608_01
case_images: PMC8710608_02
case_images: Skin response (A, B) skin at diagnosis, (C) skin after 2 week of vemurafenib treatment, (D) skin after 1 month of vemurafenib treatment.
case_images: fonc-11-794498-g001.jpg
case_images: PMC8710608_02_fonc-11-794498-g001.jpg
case_images: f1
case_images: Clinical examination revealed a purpuric disseminated rash ( Figure 1 ), cervical lymphadenopathy, and hepatosplenomegaly.
case_images: PMC8710608_03
case_images: Clinical and laboratory response to the combination of Vemurafenib with chemotherapy.
case_images: fonc-11-794498-g002.jpg
case_images: PMC8710608_04_fonc-11-794498-g002.jpg
case_images: f2
case_images: Blood counts normalized without need of blood-derived products support starting from day 8 (see  Figure 2 ).
case_images: PMC8710608_04
case_images: Clinical and laboratory response to the combination of Vemurafenib with chemotherapy.
case_images: fonc-11-794498-g002.jpg
case_images: PMC8710608_04_fonc-11-794498-g002.jpg
case_images: f2
case_images: Blood counts normalized without need of blood-derived products support starting from day 8 (see  Figure 2 ).
case_images: PMC8710608_05